Systematic biobanking, novel imaging techniques, and advanced molecular analysis for precise tumor diagnosis and therapy: The Polish MOBIT project.

Personalized and precision medicine is gaining recognition due to the limitations by standard diagnosis and treatment; many areas of medicine, from cancer to psychiatry, are moving towards tailored and individualized treatment for patients based on their clinical characteristics and genetic signatures as well as novel imaging techniques. Advances in whole genome sequencing have led to identification of genes involved in a variety of diseases. Moreover, biomarkers indicating severity of disease or susceptibility to treatment are increasingly being characterized. The continued identification of new genes and biomarkers specific to disease subtypes and individual patients is essential and inevitable for translation into personalized medicine, in estimating both, disease risk and response to therapy. Taking into consideration the mostly unsolved necessity of tailored therapy in oncology the innovative project MOBIT (molecular biomarkers for individualized therapy) was designed. The aims of the project are: (i) establishing integrative management of precise tumor diagnosis and therapy including systematic biobanking, novel imaging techniques, and advanced molecular analysis by collecting comprehensive tumor tissues, liquid biopsies (whole blood, serum, plasma), and urine specimens (supernatant; sediment) as well as (ii) developing personalized lung cancer diagnostics based on tumor heterogeneity and integrated genomics, transcriptomics, metabolomics, and radiomics PET/MRI analysis. It will consist of 5 work packages. In this paper the rationale of the Polish MOBIT project as well as its design is presented. (iii) The project is to draw interest in and to invite national and international, private and public, preclinical and clinical initiatives to establish individualized and precise procedures for integrating novel targeted therapies and advanced imaging techniques.

[1]  Ling Dong,et al.  Clinical Next Generation Sequencing for Precision Medicine in Cancer , 2015, Current genomics.

[2]  Hyun Woo Kwon,et al.  FDG Whole-Body PET/MRI in Oncology: a Systematic Review , 2017, Nuclear Medicine and Molecular Imaging.

[3]  R. Sutphen,et al.  Urine Collection and Processing for Protein Biomarker Discovery and Quantification , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[4]  S. Zhang,et al.  A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles , 2016, Molecular Medicine Reports.

[5]  Axel Benner,et al.  A Systematic Approach to Defining the microRNA Landscape in Metastasis. , 2015, Cancer research.

[6]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Y. Xiaohan,et al.  Proteomics Approaches for Identification of Tumor Relevant Protein Targets in Pulmonary Squamous Cell Carcinoma by 2D-DIGE-MS , 2014, PloS one.

[8]  J. Utikal,et al.  Function and significance of MicroRNAs in benign and malignant human stem cells. , 2015, Seminars in cancer biology.

[9]  B. Foroutan Personalized Medicine: A Review with Regard to Biomarkers , 2015 .

[10]  William E Grizzle,et al.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. , 2009, Journal of proteome research.

[11]  H. Uramoto,et al.  Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing , 2017, International journal of oncology.

[12]  Andrew D. Southam,et al.  Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics , 2016, Metabolomics.

[13]  J. Nikliński,et al.  Validation for histology‐driven diagnosis in non‐small cell lung cancer using hsa‐miR‐205 and hsa‐miR‐21 expression by two different normalization strategies , 2016, International journal of cancer.

[14]  C. Barbas,et al.  To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients , 2015, Oncotarget.

[15]  G. V. von Schulthess,et al.  Whole-body nonenhanced PET/MR versus PET/CT in the staging and restaging of cancers: preliminary observations. , 2014, Radiology.

[16]  György Marko-Varga,et al.  BioBanking as the central tool for translational medicine CTM issue 2013 , 2013, Clinical and Translational Medicine.

[17]  M. Ruchała,et al.  PET/MR - a rapidly growing technique of imaging in oncology and neurology. , 2016, Nuclear medicine review. Central & Eastern Europe.

[18]  Michael F. Ochs,et al.  Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer , 2012, PloS one.

[19]  J. Nikliński,et al.  Proteomics biomarkers for non-small cell lung cancer. , 2014, Journal of pharmaceutical and biomedical analysis.

[20]  J. Nikliński,et al.  Profiling of selected angiogenesis-related genes in serous ovarian cancer patients. , 2017, Advances in medical sciences.

[21]  Christian Manegold,et al.  Treatment algorithm in 2014 for advanced non-small cell lung cancer: therapy selection by tumour histology and molecular biology. , 2014, Advances in medical sciences.

[22]  Jacek Niklinski,et al.  MicroRNAs as novel targets and tools in cancer therapy. , 2017, Cancer letters.

[23]  H. Juhl,et al.  Identification and Validation of a Potential Marker of Tissue Quality Using Gene Expression Analysis of Human Colorectal Tissue , 2015, PloS one.

[24]  N. Lindeman,et al.  Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.